Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386504 | 0.88 | NPSR1 (0.58) | HCRTR1HCRTR2EP300ALDH1A1ENPP2 | |
| SCHEMBL13588851 | 0.88 | NPSR1 (0.58) | HCRTR1HCRTR2EP300ALDH1A1ENPP2 | |
| SCHEMBL4389357 | 0.85 | NPSR1 (0.55) | HCRTR1HCRTR2ALDH1A1ENPP2MEN1 | |
| SCHEMBL13588977 | 0.85 | NPC1 (0.58) | ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL13588979 | 0.84 | EP300 (0.56) | HCRTR1HCRTR2EP300ALDH1A1CFD | |
| SCHEMBL4392318 | 0.84 | EP300 (0.56) | HCRTR1HCRTR2EP300ALDH1A1CFD | |
| SCHEMBL4386769 | 0.82 | ALDH1A1 (0.51) | HCRTR1HCRTR2ALDH1A1ENPP2MEN1 | |
| SCHEMBL474945 | 0.82 | HCRTR1 (0.55) | HCRTR1HCRTR2ALDH1A1MAPTUSP2 | |
| SCHEMBL10173437 | 0.82 | HCRTR1 (0.55) | HCRTR1HCRTR2ALDH1A1MAPTUSP2 | |
| SCHEMBL20966532 | 0.82 | HCRTR1 (0.55) | HCRTR1HCRTR2ALDH1A1MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629340-B2 | N-(6-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629340-B2 | N-(6-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265262-A1 | N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, HAVCR2, ZC3HAV1L | HCRTR1 1582/4885HCRTR2 2570/4885EP300 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.